CT SB00138

Manufacturers and wholesalers registered in Connecticut must make brand-name drugs distributed in the state available for sale to generic drug developers for testing purposes at a price not exceeding the wholesale acquisition cost.

Sales must occur without restrictions that would block or delay a generic drug developer's application in a manner inconsistent with federal Food, Drug, and Cosmetic Act Section 505-1(f)(8).

Generic drug developers receiving drugs at wholesale acquisition cost must charge Connecticut consumers the same price or less for their manufactured versions.

Brand-name manufacturers and wholesalers are shielded from liability for injuries caused by inadequate safety warnings or design defects in generic products they supplied, provided the generic product was not manufactured or sold by them.

Violations of the drug availability or pricing requirements are classified as unfair or deceptive trade practices under Connecticut law, effective October 1, 2020.